Degradable cationic polymer with bone targeting function as well as preparation method and application thereof

By developing degradable cationic polymers with bone-targeting function to form nanocomplexes with nucleic acids, the penetration and accumulation of nucleic acid delivery in the treatment of bone-related diseases has been solved, and efficient, stable and targeted nucleic acid delivery has been achieved, which has significantly improved the Treatment effects and reduce side effects.

CN118894986AActive Publication Date: 2024-11-05TONGJI UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410922729.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-05
Estimated Expiration
2044-07-10

AI Technical Summary

Technical Problem

In the treatment of bone-related diseases, existing nucleic acid delivery vehicles are difficult to effectively penetrate and accumulate in bone tissue, resulting in poor treatment effects and may cause side effects, and traditional vectors have problems with cytotoxicity, instability and lack of targeting.

Method used

A degradable cationic polymer with bone-targeting function was developed to provide protection by forming nanocomplexes with nucleic acids, utilizing electrostatic interactions, and to achieve the Accurate delivery of bone tissue.

Benefits of technology

It achieves efficient nucleic acid loading rate and protection, significantly improves treatment efficiency, has excellent stability and clear bone targeting performance, reduces side effects, and shows good biocompatibility and extensive medical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894986A_ABST
    Figure CN118894986A_ABST
Patent Text Reader

Abstract

The invention relates to a degradable cationic polymer with a bone targeting function as well as a preparation method and application thereof, in particular to the degradable cationic polymer with the bone targeting function, which can effectively load nucleic acid (such as mRNA (messenger ribonucleic acid), miRNA (micro ribonucleic acid) and DNA (deoxyribonucleic acid)), the entrapment rate exceeds 90%, stable nano-particles are formed through electrostatic interaction, the nucleic acid is protected from being degraded, and the degradable cationic polymer with the bone targeting function can be used for preparing the bone targeting function. Meanwhile, the positive electricity of particles is slowed down. Compared with LNP, the carrier shows better stability and supports low-temperature long-term storage. The bone targeting property is definite, nucleic acid is promoted to be accurately delivered to bone tissues, the curative effect is enhanced, the side effect is reduced, and meanwhile, the non-toxic biocompatibility to osteoblasts is shown. The application range is wide, and osteoporosis, osteoarthritis, bone tumor treatment and gene and stem cell treatment are covered. Experiments prove that the transfection efficiency of nano-particles formed by the carrier and eGFP mRNA is high, the bone metastasis of breast cancer is effectively inhibited by combining the carrier with miRNA, and the treatment potential of the carrier is highlighted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of polymer material science and biomedicine, and in particular relates to a degradable cationic polymer with bone targeting function and a preparation method and application thereof. Background Art

[0002] Gene therapy, as a cutting-edge treatment method, provides new ideas for the treatment of various diseases by specifically regulating gene expression in specific cells. The implementation of this method relies on the effective delivery of nucleic acids, such as DNA, mRNA, saRNA, siRNA, miRNA, etc. These nucleic acid molecules are key mediators of gene regulation. However, due to the large size and hydrophilicity of nucleic acid molecules, they are difficult to cross the cell membrane alone, especially when administered systemically, and multiple physiological barriers need to be overcome to reach the site of action. At present, although traditional delivery platforms such as viral vectors, lipid nanocomplexes and polymers have been widely studied, they each have limitations, such as cytotoxicity, instability and lack of targeting.

[0003] Polymer materials have shown significant advantages in the field of nucleic acid delivery due to their versatility, scalability and precise controllability. By adjusting the structure and molecular weight of the polymer and performing specific modifications, polymer nucleic acid delivery systems that can target different organs have been successfully developed. In particular, cationic polymers, which combine with negatively charged nucleic acids through electrostatic interactions to form nanocomplexes, provide protection for nucleic acids to cross biological barriers, and achieve precise organ targeting by regulating the physical properties of the nanocomplexes.

[0004] In the treatment of bone-related diseases, the unique extracellular matrix of bone tissue and the complex bone marrow microenvironment make it difficult for drugs to effectively penetrate and accumulate in the lesion site. This non-specific biodistribution not only affects the therapeutic effect, but may also cause unnecessary side effects to patients. Therefore, it is particularly important to develop stable, efficient and degradable bone-targeted nucleic acid delivery carriers that can ensure that nucleic acid drugs reach the target site accurately and safely, thereby exerting the best therapeutic effect. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a degradable cationic polymer with bone targeting function and a preparation method and application thereof. The polymer provided by the present invention has bone targeting function, and the nanoparticles prepared using the polymer as a carrier have good bone targeting performance, and have great application potential in the prevention, improvement or treatment of osteoporosis, osteoarthritis, bone tumors and other bone-related diseases, gene therapy, stem cell therapy and other medical treatments.

[0006] Specifically, the present invention provides a polymer or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof, characterized in that the polymer has a structural formula as shown in formula (I):

[0007]

[0008] In formula (I):

[0009] R' is selected from L 1 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0010] R" is selected from Optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0011] M does not exist or is -SS-;

[0012] R 1 , R 2 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl;

[0013] R"' is selected from -L 5 -R 3 ;

[0014] R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ;

[0015] R 11 and R 12are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C 6-12 Aryl or optionally substituted 5-10 membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkenyl group may also be randomly interrupted by one or more heteroatoms;

[0016] m is an integer between 1 and 10;

[0017] R"" is selected from L 4 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0018] Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0019] The range of y / x+y is 0-0.5.

[0020] In some specific embodiments of the present invention,

[0021] R' is selected from L 1 ;

[0022] R" is selected from

[0023] M does not exist or is -SS-;

[0024] R 1 , R 2 are each independently hydrogen, optionally substituted C 1-12Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl;

[0025] R"' is selected from -L 5 -R 3 ;

[0026] R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ;

[0027] R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkylene or alkylene alkyne may also be randomly interrupted by one or more heteroatoms;

[0028] m is an integer between 1 and 10;

[0029] R"" is selected from L 4 ;

[0030] Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0031] The range of y / x+y is 0-0.5.

[0032] In some specific embodiments of the present invention, the L 1 To L4 are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted 3- to 8-membered heterocycloalkyl.

[0033] In some specific embodiments of the present invention, the L 5 is an optionally substituted C 2-8 Alkyl, optionally substituted C 2-8 Alkenyl or optionally substituted C 2-6 Alkynyl, wherein adjacent carbon atoms in an alkyl, alkenyl or alkynyl group may be randomly interrupted by one or more heteroatoms.

[0034] In some specific embodiments of the present invention, R 1 , R 2 are independently selected from hydrogen.

[0035] In some specific embodiments of the present invention, R 3 They are -OH, -COOH, -SO3H, -NH2, -N(CH3)2, -N(CH2CH3)2.

[0036] In some specific embodiments of the present invention, the structure of formula (I) is selected from the following structural formulas:

[0037]

[0038]

[0039]

[0040] Among them, the range of y / x+y is 0-0.5.

[0041] In some specific embodiments of the present invention, the average molecular weight of the polymer represented by formula (I) is greater than 5 kg / mol and less than 150 kg / mol.

[0042] In some specific embodiments of the present invention, the average molecular weight of the polymer represented by formula (Ih) is at least 5.5 kg / mol, at least 6 kg / mol, at least 7 kg / mol, at least 8 kg / mol, at least 9 kg / mol, at least 10 kg / mol, at least 12 kg / mol, at least 14 kg / mol, at least 16 kg / mol, at least 18 kg / mol, at least 20 kg / mol, at least 22 kg / mol or at least 24 kg / mol.

[0043] The present invention also provides a degradable cationic polymer with bone targeting function or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof, characterized in that the polymer has a structural formula as shown in formula (I):

[0044]

[0045] In formula (I):

[0046] R' is selected from L 1 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0047] R" is selected from Optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0048] M does not exist or is -SS-;

[0049] R 1 , R 2 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl;

[0050] R"' is selected from -L 5 -R 3 ;

[0051] R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ;

[0052] R 11 and R12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C 6-12 Aryl or optionally substituted 5-10 membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkenyl group may also be randomly interrupted by one or more heteroatoms;

[0053] m is an integer between 1 and 10;

[0054] R"" is selected from L 4 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0055] Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0056] The range of y / x+y is 0-0.5.

[0057] In some specific embodiments of the present invention,

[0058] R' is selected from L 1 ;

[0059] R" is selected from

[0060] M does not exist or is -SS-;

[0061] R 1 , R 2 are each independently hydrogen, optionally substituted C1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl;

[0062] R"' is selected from -L 5 -R 3 ;

[0063] R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ;

[0064] R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkylene or alkylene alkyne may also be randomly interrupted by one or more heteroatoms;

[0065] m is an integer between 1 and 10;

[0066] R"" is selected from L 4 ;

[0067] Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms;

[0068] The range of y / x+y is 0-0.5.

[0069] In some specific embodiments of the present invention, the L1 To L 4 are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted 3- to 8-membered heterocycloalkyl.

[0070] In some specific embodiments of the present invention, the L 5 is an optionally substituted C 2-8 Alkyl, optionally substituted C 2-8 Alkenyl or optionally substituted C 2-6 Alkynyl, wherein adjacent carbon atoms in an alkyl, alkenyl or alkynyl group may be randomly interrupted by one or more heteroatoms.

[0071] In some specific embodiments of the present invention, R 1 , R 2 are independently selected from hydrogen.

[0072] In some specific embodiments of the present invention, R 3 They are -OH, -COOH, -SO3H, -NH2, -N(CH3)2, -N(CH2CH3)2.

[0073] In some specific embodiments of the present invention, the structure of formula (I) is selected from the following structural formulas:

[0074]

[0075]

[0076]

[0077] Among them, the range of y / x+y is 0-0.5.

[0078] In some specific embodiments of the present invention, the average molecular weight of the polymer represented by formula (I) is greater than 5 kg / mol and less than 150 kg / mol.

[0079] In some specific embodiments of the present invention, the average molecular weight of the polymer represented by formula (Ih) is at least 5.5 kg / mol, at least 6 kg / mol, at least 7 kg / mol, at least 8 kg / mol, at least 9 kg / mol, at least 10 kg / mol, at least 12 kg / mol, at least 14 kg / mol, at least 16 kg / mol, at least 18 kg / mol, at least 20 kg / mol, at least 22 kg / mol or at least 24 kg / mol.

[0080] The present invention also provides a method for preparing a salt of a polymer described in formula (Ij) or formula (Ik), comprising the following preparation steps: adding N,N'-(propane-1,3-diyl)diacrylamide or N,N'-bis(acryloyl)cystamine and a compound of formula (II), alendronic acid and triethylamine to a flask equipped with a stirring bar, and also adding a mixed solvent of methanol and water to the flask; then reacting in a dark environment at 40-60°C under a nitrogen atmosphere; reacting for 5 to 14 days to produce a highly viscous solution, taking out aliquots at predetermined time intervals for detection to monitor the conversion rate and molar mass, and once the target molar mass is reached, diluting with MeOH to stop the reaction; then acidifying the diluted reaction mixture to an acidic environment with HCl, and then purifying it by dialyzing against acidic water, and then freeze-drying the purified product, and collecting the polymer in the form of its hydrochloride as a solid after freeze-drying;

[0081]

[0082] The structural formula of the compound of formula (II) is as follows:

[0083]

[0084] Among them, the range of y / x+y is 0-0.5;

[0085] L 5 is an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl groups are randomly interrupted by one or more heteroatoms;

[0086] R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ;

[0087] R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C3-6 Cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C 6-12 aryl or optionally substituted 5-10 membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkenyl radical are optionally interrupted by one or more heteroatoms;

[0088] m is an integer between 1 and 10.

[0089] In some specific embodiments of the present invention, the compound of formula (Ij) is prepared using N,N'-(propane-1,3-diyl)diacrylamide and the compound of formula (II), alendronic acid and triethylamine as raw materials.

[0090] In some specific embodiments of the present invention, the compound of formula (Ik) is prepared by using N,N'-bis(acryloyl)cystamine with the compound of formula (II), alendronic acid and triethylamine.

[0091] In some specific embodiments of the present invention, the molar ratio of bisacrylamide, the compound represented by formula (III), alendronic acid and triethylamine is 10:9:1:1.

[0092] In some specific embodiments of the present invention, the volume ratio of methanol to water is 4:1.

[0093] In some specific embodiments of the present invention, the reaction temperature is 50°C.

[0094] In some specific embodiments of the present invention, the method of taking out aliquots of samples for testing at predetermined time intervals is to take out aliquots of samples for nuclear magnetic resonance spectroscopy ( 1 H NMR) and gel permeation chromatography (SEC) detection.

[0095] In some specific embodiments of the present invention, the concentration of HCl used in the diluent is 1.0M.

[0096] In some specific embodiments of the present invention, the acidic environment has a pH of 4. In some specific embodiments of the present invention, purification is performed by dialysis against acidic water (4.0 L, pH=5, changed 6 times within 3 days).

[0097] The present invention also provides a bone-targeted nucleic acid delivery vector, characterized in that it comprises the above polymer or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof.

[0098] The present invention also provides a nanocomplex comprising the above polymer or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof and nucleic acid.

[0099] In some specific embodiments of the present invention, the nucleic acid is selected from at least one of DNA, RNA, plasmid or DNA / RNA hybrid sequence.

[0100] In some specific embodiments of the present invention, the RNA is selected from at least one of agonist RNA, microRNA, short interfering RNA, short hairpin RNA, self-amplifying RNA, interfering RNA and small RNA.

[0101] In some specific embodiments of the invention, the RNA is a microRNA.

[0102] In some specific embodiments of the present invention, the weight ratio of the polymer to the nucleic acid is between 5:1 and 100:1.

[0103] The present invention also provides a nanoparticle comprising the above polymer or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof or the above nanocomposite.

[0104] In some embodiments of the present invention, the nanoparticles have a hydrodynamic mean diameter D of less than 1000 nanometers. h ;

[0105] Preferably, the nanoparticles have a hydrodynamic mean diameter D of less than 200 nanometers. h .

[0106] The present invention also provides a pharmaceutical composition, characterized in that it includes the above-mentioned polymer or its pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph, a polymer prepared by the preparation method of the above-mentioned polymer, the above-mentioned bone-targeted nucleic acid delivery vector, the above-mentioned nanocomplex, and the above-mentioned nanoparticle.

[0107] In some specific embodiments of the present invention, the above-mentioned pharmaceutical composition further comprises a drug to be delivered and a pharmaceutically acceptable excipient.

[0108] Use of the above-mentioned polymer or its pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph, the polymer prepared by the method for preparing the polymer as described in claim 10, the bone-targeted nucleic acid delivery vector as described in claim 11, the nanocomplex as described in any one of claims 12-16, and the nanoparticle as described in any one of claims 17-18 in the preparation of drugs for stimulating and enhancing protective immune responses, gene therapy drugs, or drugs for preventing, improving or treating bone-related diseases.

[0109] In some specific embodiments of the present invention, the bone-related disease is at least one of osteoporosis, osteoarthritis or bone tumor.

[0110] The polymer provided by the present invention has a series of significant beneficial technical effects, which are mainly reflected in the following aspects:

[0111] (1) Highly efficient nucleic acid encapsulation and protection: The cationic polymer provided by the present invention can be complexed with a variety of RNAs such as messenger RNA (mRNA), microRNA (miRNA) and nucleic acids such as DNA, and can achieve a nucleic acid encapsulation rate of more than 90%, which ensures the effective delivery of nucleic acid drugs and a high therapeutic efficiency; in addition, the cationic polymer can form nanoparticles by combining the positive charge on its surface with the negatively charged nucleic acid through electrostatic interaction, thereby protecting the nucleic acid from degradation and reducing the positive charge on the particle surface.

[0112] (2) Excellent stability: Compared with the traditional nucleic acid delivery carrier LNP, the nanoparticles of the present invention are more stable and can be stored for a long time at 4°C, which facilitates the long-term storage and transportation of nucleic acid drugs.

[0113] (3) Clear bone targeting performance: By introducing the alendronic acid group with bone targeting function and bone repair pharmacological effect into the side chain, the present invention endows the cationic polymer nucleic acid delivery vector with clear bone targeting performance. This enables the nucleic acid drug to reach the bone tissue more accurately, thereby improving the therapeutic effect and reducing side effects.

[0114] (4) Good biocompatibility: Both the degradable cationic polymer with bone targeting function provided by the present invention and the nanoparticles based on the polymer provided by the present invention are non-toxic to normal osteoblasts and show good biocompatibility.

[0115] (5) Broad application prospects: The degradable cationic polymer with bone-targeting function and the polymer-based bone-targeting nucleic acid delivery vector provided by the present invention can be widely used in the medical field, including prevention, improvement or treatment of bone-related diseases such as osteoporosis, osteoarthritis and bone tumors; gene therapy; stem cell therapy, etc.

[0116] (6) Highly effective therapeutic effect: Experiments have shown that the nanoparticles formed by the complex of the bone-targeted polymer and eGFP mRNA have high transfection efficiency; combined with miRNA, it can achieve the effect of treating bone metastasis of breast cancer, demonstrating its great potential in actual treatment.

[0117] In summary, the degradable cationic polymer with bone targeting function proposed in the present invention and the nanoparticles, nanocomplexes and nucleic acid delivery vectors based thereon have the advantages of high efficiency, stability, strong targeting, good biocompatibility and significant therapeutic effect, etc., which provide a new solution for the delivery of nucleic acid drugs and have broad application prospects and important medical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0118] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0119] Figure 1 Comparison of the in vitro bone targeting ability of polymers with different alendronic acid contents.

[0120] Figure 2 This is a transmission electron microscopy image of the nanocomposite formed by the composite.

[0121] Figure 3 This is the DLS particle size test curve of the nanocomposite obtained by titration method.

[0122] Figure 4 This is the stability test curve of the nanocomplex stored at 4°C obtained by titration method.

[0123] Figure 5 This is the degradation curve of bone-targeted polymer / miRNA nanocomplex in the presence of glutathione.

[0124] Figure 6 The fluorescence expression of MDA-MB-231 human breast cancer cells after the nanocomplex formed by polymers with different alendronic acid contents and FAM-labeled miRNA was transfected into the cells.

[0125] Figure 7 The cytotoxicity test data on MDA-MB-231 human breast cancer cells after encapsulating miRNA in different delivery systems.

[0126] Figure 8 The cytotoxicity test data on MC3T3-E1 osteoblasts after encapsulating miRNA in different delivery systems.

[0127] Fig. 9 The expression of fluorescent proteins after HEK-293T human embryonic kidney cells were transfected with different polymer / mRNA nanocomplexes.

[0128] Fig.10 Effects of bone-targeted polymer / miRNA nanocomplexes on MDA-MB-231 human breast cancer cells.

[0129] Fig.11 The effect of bone-targeted polymer / miRNA nanocomplex on the proliferation ability of MC3T3-E1 osteoblasts.

[0130] Fig.12 Comparison of the in vivo bone targeting capabilities of different polymer / miRNA nanocomplexes. DETAILED DESCRIPTION

[0131] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention and should not be used to limit the protection scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work belong to the protection scope of the present invention.

[0132] Example 1: Synthesis of polymers with different alendronic acid grafting ratios

[0133] N,N'-bis(acryloyl)cystamine (1 mmol), 4-aminobutanol, alendronic acid (total 1 mmol) and triethylamine (0.1 mmol) were added to a flask equipped with a stirring bar, and a mixed solvent of methanol / water (4 / 1, v / v) was also added to the flask. The polymerization reaction was carried out in a dark environment at 50°C under a nitrogen atmosphere. The mixture was allowed to react for 5 to 14 days (depending on the target molecular weight) to produce a highly viscous solution. Aliquots were taken out at predetermined time intervals for H NMR spectroscopy ( 1 HNMR) and gel permeation chromatography (SEC) to monitor conversion and molar mass. Once the target molar mass is reached, the reaction is stopped by dilution with MeOH. The diluted reaction mixture is then acidified to pH ~ 4 with 1.0M HCl and then purified by dialysis against acidic water (4.0L, pH ~ 5, changed 6 times in 3 days). The polymer in its hydrochloride form is collected as a white solid after lyophilization. Among them, the structural formula of the polymer is shown below (Ia1):

[0134] y / x+y is shown in Table 1 below.

[0135]

[0136] Table 1 Polymers with different alendronic acid grafting ratios

[0137]

[0138] Example 2: Synthesis of polymers with different grafted monomers

[0139] N,N'-bis(acryloyl)cystamine or N,N'-(propane-1,3-diyl)diacrylamide (1 mmol), the compound represented by formula (II) (0.9 mmol), alendronic acid (0.1 mmol) and triethylamine (0.1 mmol) were added to a flask equipped with a stirring bar, and a mixed solvent of methanol / water (4 / 1, v / v) was also added to the flask. The polymerization reaction was carried out in a dark environment at 50°C under a nitrogen atmosphere. The mixture was allowed to react for 5 to 14 days (depending on the target molecular weight) to produce a highly viscous solution. Aliquots were taken out at predetermined time intervals for nuclear magnetic proton spectroscopy ( 1 HNMR) and gel permeation chromatography (SEC) to monitor conversion and molar mass. Once the target molar mass is reached, the reaction is stopped by dilution with MeOH. The diluted reaction mixture is then acidified to pH ~ 4 with 1.0 M HCl and then purified by dialysis against acidic water (4.0 L, pH ~ 5, changed 6 times in 3 days). The polymers collected in the form of their hydrochloride salts after lyophilization are white solids with the structural formulas (Ib1), (Id1), and (Ih1), respectively.

[0140]

[0141] In formula (II), L5 is -(CH2)3-, and R3 is -COOH; or L5 is -(CH2)3-, and R3 is -OH; or L5 is -(CH2)4-, and R3 is -OH.

[0142] The structural formula of the polymer is shown below:

[0143]

[0144] The polymer molecular weights are shown in Table 2 below.

[0145] Table 2 Polymers with different grafted monomers

[0146]

[0147] Example 3: In vitro bone targeting ability of polymers with different alendronic acid contents

[0148] The polymers (25 mg) with different alendronic acid contents prepared in Example 1 were dissolved in deionized water (5 mL) respectively, and then fluorescein isothiocyanate (FITC) (1 mg) dissolved in 100 μL DMF was added to the polymer solution. The mixture was allowed to react in the dark at 25°C for 24 hours. The reaction mixture was then dialyzed with acidic water (pH ~ 5, refreshed 6 times within 3 days) in the dark (molecular weight cutoff is 3.5 kDa). After freeze-drying, the fluorescently labeled polymer was collected as a yellow solid. The FITC-labeled bone-targeted polymer and the FITC-labeled non-targeted polymer were dissolved in deionized water to 0.2 mg / mL, and the initial fluorescence intensity (I t0 Then, hydroxyapatite powder (10.0 mg) was added to 1.50 mL of FITC-labeled polymer solution, stirred continuously at 37°C for 6.0 hours, and then centrifuged to measure the fluorescence intensity of the supernatant (I t The binding rate of polymer to hydroxyapatite (HAP binding rate) was calculated according to the following formula: HAP binding rate = (I t0 -I t ) / I t0 ×100%. The binding rate of pABOL to hydroxyapatite is 69.04%, the binding rate of polymer with 5% alendronic acid molar percentage to hydroxyapatite is 84.34%, the binding rate of polymer with 10% alendronic acid molar percentage to hydroxyapatite is 86.1%, and the binding rate of polymer with 20% alendronic acid molar percentage to hydroxyapatite is 87.18%. The comparative data of in vitro bone targeting ability of polymers with different alendronic acid contents are shown in the attached figure. Figure 1 shown.

[0149] Example 4: Preparation of nanocomplexes by combining bone-targeting polymers with different nucleic acids

[0150] Before the experiment, RNase free ultrapure water was used to prepare HEPES buffer containing 20mM HEPES, 5.0wt% glucose, pH=7, and sterilized by filtration with a 0.22μm PES filter. Use RNase free ultrapure water to prepare 1.0μg / μL RNA and 10μg / μL polymer master solution. When titrating, dilute to the corresponding concentration with different volumes of HEPES buffer as needed. Take the preparation of a nanocomplex with a polymer / miRNA mass ratio of 20 / 1 (μg / μg) and a final miRNA concentration of 100μg / mL as an example. Take 10μL of miRNA master solution and add it to a 2.0mL sterile centrifuge tube, add 50μL of pH=7 HEPES buffer to dilute and mix thoroughly to obtain miRNA buffer. Take 20μL of polymer master solution in a 2.0mL sterile centrifuge tube, add 20μL of pH=7 HEPES buffer and mix thoroughly to obtain polymer buffer. Then, the miRNA buffer was dripped into the polymer buffer at a dripping rate of 160 μL / min by a syringe pump. During the dripping process, the speed of 1200 r / min was maintained for magnetic stirring. After the dripping was completed, stirring was continued for 30 minutes until a stable polymer / miRNA nanocomplex was formed. The nanocomplex with pH = 7, 10% ALN-pABOL / miRNA = 15 / 1 (w / w) was dripped on the carbon film side of the copper mesh and dried at room temperature. Then, it was stained with 1% phosphotungstic acid solution, dried, and observed under a transmission electron microscope. The results are shown in the attached figure. Figure 2 As shown, the morphology of the nanocomposite is spherical particles with a particle size of about 200 nm. The DLS characterization results of the nanocomposite are shown in Table 3 below, wherein the DLS particle size test curve of the nanocomposite at pH = 7, 10% ALN-pABOL / miRNA = 15 / 1 (w / w) is shown in the attached Figure 3 As shown, the hydrodynamic diameter (D h ) is 212.2 nm and the polydispersity (PD) is 0.006.

[0151] Table 3 Parameter settings and DLS characterization results during the preparation of nanocomposites

[0152]

[0153] Example 5: In vitro stability and GSH responsiveness of bone-targeting polymer / miRNA complexes

[0154] The nanocomplexes of pH = 7, 10% ALN-pABOL / miRNA = 20 / 1 (w / w) were stored in HEPES buffer (20 mM HEPES, 5 wt% glucose, pH 7.0) at 4°C. The hydrodynamic diameter (D h) and polydispersity (PD) every other day. The results are shown in the attached Figure 4 As shown, after the nanocomplex was stored at 4°C for two weeks, its hydrodynamic diameter (D h ) remained below 300 nm and the polydispersity (PD) remained below 0.2, indicating good in vitro stability.

[0155] A 10% ALN-pABOL / miRNA=20 / 1 (w / w) nanocomplex with a miRNA concentration of 10 μg / mL was prepared in a HEPES buffer containing 20 mM HEPES, 5.0 wt% glucose, pH = 7. 20 μL of a 100 mM reduced glutathione aqueous solution was added to 180 μL of the complex solution, and the hydrodynamic diameter (D ) of the 10% ALN-pABOL / miRNA nanocomplex was measured by dynamic light scattering (DLS) at 25°C within 5 hours. h ), polydispersity (PD) changes over time. The results are shown in the attached Figure 5 As shown in the figure, the hydrodynamic diameter (D h ) increased to above 1000 nm and the polydispersity (PD) increased to above 0.3, indicating that it has good GSH responsiveness.

[0156] Example 6: Cellular Uptake of Bone-Targeted Polymer / miRNA Complexes

[0157] In HEPES buffer (20 mM HEPES, 5 wt% glucose aqueous solution, pH = 7), PEI, pABOL, 10% ALN-pABOL, 20% ALN-pABOL and 5-carboxyfluorescein (5-FAM, excitation / emission wavelength 492 / 520 nm) labeled FAM-miRNA were used in a mass ratio of 20:1 to prepare nanocomplexes with a miRNA concentration of 1000 nM. MDA-MB-231 human breast cancer cells were cultured at 6 × 10 3 The cells were inoculated at a density of 100 μL / well in a 96-well plate, cultured in 100 μL complete medium for 24 hours, and then the medium was changed. Each well was washed 3 times with 100 μL PBS. 10 μL of polymer / miRNA complex buffer was evenly mixed with 90 μL serum-free and dual-antibody-free medium and added to the 96-well plate, and co-cultured with the cells for 3 hours. After the corresponding transfection time, the medium was removed, each well was washed 3 times with 100 μL PBS, and then tested with a fluorescent microplate reader. The test results are shown in the attached Figure 6 As shown, the results showed that the uptake efficiency of MDA-MB-231 human breast cancer cells after co-culture with different nanocomplexes for 3 hours was higher than that of the nanocomplex formed by commercial PEI and miRNA, and had a high uptake efficiency.

[0158] Example 7: Cytotoxicity of bone-targeted polymer / miRNA complexes

[0159] Test the cytotoxicity of bone-targeted polymer / miRNA complexes: PEI / miRNA, Lipo / miRNA, pABOL / miRNA, and 10% ALN-pABOL / miRNA nanocomplex solutions with miRNA concentrations of 13.3 μg / mL, 6.65 μg / mL, 3.33 μg / mL, 1.67 μg / mL, and 0.835 μg / mL were prepared in HEPES buffer at the optimal ratio using the half-dilution method. MDA-MB-231 human breast cancer cells or MC3T3-E1 osteoblasts were cultured at 8.0×10 3 Each well was inoculated in a 96-well plate and cultured in 100 μL DMEM or α-MEM complete medium for 24 hours, and the medium was changed. 10 μL of different nanocomplex solutions of different concentrations and 90 μL of serum-free and dual-antibody-free medium were added to each well. Three replicate wells were set for each concentration of each material, and the medium was changed after 8 hours of co-culture. 10 μL CCK-8 colorimetric solution and 100 μL of fresh complete medium were added to each well and cultured for 2-4 hours. The absorbance of each well at 450 nm was tested with an ELISA instrument, and cells not co-cultured with the nanocomplex solution were used as the control group. The cytotoxicity of the material was characterized by the relative cell viability of each group of cells, and the relative cell viability can be calculated according to the following formula, where A s Represents the absorbance of the experimental well, A c represents the absorbance of the control well, A b The results showed that the 10% ALN-pABOL / miRNA=20 / 1 (w / w) nanocomplex showed no cytotoxicity to MDA-MB-231 human breast cancer cells and MC3T3-E1 osteoblasts (the test data are shown in Figure 7 and Figure 8 shown).

[0160]

[0161] Example 8: In vitro transfection of bone-targeted polymer / mRNA complexes

[0162] To test the in vitro transfection effect of bone-targeted polymer / mRNA complexes: In HEPES buffer (20 mM HEPES, 5 wt% glucose aqueous solution, pH 7.4), PEI, pABOL, 10% ALN-pABOL and eGFP mRNA (eGFP, excitation / emission wavelength 488 / 507 nm) were used to prepare nanocomplex solutions with an mRNA concentration of 1000 nM. One day before transfection, HEK-293T human embryonic kidney cells were cultured at 8.0 × 10 3 Each well was inoculated with 100 μL DMEM complete medium for 24 hours, and then the medium was changed. 10 μL of nanocomplex solution and 90 μL of serum-free and dual-antibody-free medium were added to each well. Three replicate wells were set for each material. After 4 hours of co-culture, 100 μL of fresh complete medium was replaced. After another 24 hours of culture, the transfection status was observed under a fluorescence microscope. Fluorescence imaging is shown in the attached figure. Fig. 9 As shown, from left to right are the transfection effects of PEI / mRNA, pABOL / mRNA, and 10% ALN-pABOL / mRNA nanocomplexes. The results show that pABOL / mRNA and 10% ALN-pABOL / mRNA nanocomplexes have similar and efficient in vitro transfection efficiencies as the commercial transfection reagent PEI.

[0163] Example 9: Effect of bone-targeted polymer / miRNA complex on cell proliferation

[0164] In HEPES buffer (20 mM HEPES, 5 wt% glucose aqueous solution, pH 7.4), a 10% alendronic acid polymer and miRNA were used in a mass ratio of 20:1 to prepare a nanocomplex with a miRNA concentration of 1000 nM. MDA-MB-231 human breast cancer cells and MC3T3-E1 osteoblasts were cultured at 8.0 × 10 3 The cells were seeded at a density of 100 μL / well on a 96-well plate (each group had at least 3 replicate wells), and the medium was changed after culturing in 100 μL DMEM medium for 24 hours. Each well was washed 3 times with 50 μL PBS, and 10 μL of bone-targeted polymer / miRNA complex buffer or PBS was evenly mixed with 90 μL serum-free and double-antibody-free medium and added to the 96-well plate. After 8 hours of co-culture, the medium was changed, and each well was washed 3 times with 50 μL PBS, and 100 μL DMEM complete medium was added. CCK-8 was added at the 24th, 48th, 72nd and 96th hours of culture, respectively. The absorbance of each group of cells at 450 nm was monitored over time using an enzyme reader. All CCK-8 tests were performed three times to evaluate cell viability. The test results are shown in the attached Fig.10 and 11As shown, the results showed that 10% ALN-pABOL / miRNA complex could significantly inhibit the proliferation of MDA-MB-231 human breast cancer cells, but had no significant effect on the proliferation of MC3T3-E1 osteoblasts.

[0165] Example 10: In vivo bone targeting ability of bone targeting polymer / miRNA complexes

[0166] In HEPES buffer (20mM HEPES, 5wt% glucose aqueous solution, pH7.4), a polymer with a molar percentage of 10% alendronic acid and Cy5-labeled miRNA were used in a mass ratio of 20:1 to prepare a nanocomplex with a miRNA concentration of 100μg / ml. Two 5-week-old female BALB / c nude mice of similar weight were intravenously injected with 100μL of pABOL / miRNA complex and 10% ALN-pABOL / miRNA complex, and the mice were monitored using an in vivo imaging system (IVIS) at 1h, 4h, 24h, and 48h after administration. After 48h, the heart, liver, spleen, lung, kidney, tibia, femur, spine and other major organ tissues of the two mice were taken for IVIS imaging. The test results are shown in the attached figure. Fig.12 As shown, the results showed that the 10% ALN-pABOL / miRNA complex had obvious bone targeting performance compared with the pABOL / miRNA complex.

[0167] The protection content of the present invention is not limited to the above embodiments. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention and are protected by the attached claims.

[0168] Although the present invention is described using the above embodiments, it should be understood that the present invention may be further modified and varied without departing from the spirit of the present invention, and these modifications and variations are all within the scope of protection of the present invention.

Claims

1. A polymer or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof, characterized in that: The polymer has a structural formula as shown in formula (I): Where: R' is selected from L 1 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms; R" is selected from Optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms; M does not exist or is -SS-; R 1 , R 2 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl; R"' is selected from -L 5 -R 3 ; R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ; R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C 6-12 Aryl or optionally substituted 5-10 membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkenyl group may also be randomly interrupted by one or more heteroatoms; m is an integer between 1 and 10; R"" is selected from L 4 , optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 alkynyl, optionally substituted 3 to 8 membered cycloalkyl, optionally substituted 3 to 8 membered cycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms; Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms; The range of y / x+y is 0-0.

5.

2. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 1, characterized in that: R' is selected from L 1 ; R" is selected from M does not exist or is -SS-; R 1 , R 2 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl; R"' is selected from -L 5 -R 3 ; R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ; R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkylene or alkylene alkyne may also be randomly interrupted by one or more heteroatoms; m is an integer between 1 and 10; R"" is selected from L 4 ; Among them, L 1 To L 5 are each independently an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl group may also be randomly interrupted by one or more heteroatoms; The range of y / x+y is 0-0.

5.

3. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 2, characterized in that: The L 1 To L 4 are each independently an optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted 3- to 8-membered heterocycloalkyl.

4. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 2, characterized in that: The L 5 is an optionally substituted C 2-8 Alkyl, optionally substituted C 2-8 Alkenyl or optionally substituted C 2-6 Alkynyl, wherein adjacent carbon atoms in an alkyl, alkenyl or alkynyl group may be randomly interrupted by one or more heteroatoms.

5. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 1, characterized in that: R 1 , R 2 are independently selected from hydrogen.

6. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 1, characterized in that: R 3 They are -OH, -COOH, -SO3H, -NH2, -N(CH3)2, -N(CH2CH3)2.

7. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 2, characterized in that: The structure of formula (I) is selected from the following structural formulas: Among them, the range of y / x+y is 0-0.

5.

8. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to any one of claims 1 to 7, characterized in that: The average molecular weight of the polymer represented by formula (I) is greater than 5 kg / mol and less than 150 kg / mol.

9. The polymer or pharmaceutically acceptable complex, salt, solvate, tautomer or polymorph thereof according to claim 7, characterized in that: The average molecular weight of the polymer represented by formula (Ih) is at least 5.5 kg / mol, at least 6 kg / mol, at least 7 kg / mol, at least 8 kg / mol, at least 9 kg / mol, at least 10 kg / mol, at least 12 kg / mol, at least 14 kg / mol, at least 16 kg / mol, at least 18 kg / mol, at least 20 kg / mol, at least 22 kg / mol or at least 24 kg / mol.

10. A method for preparing a salt of a polymer described in formula (Ij) or formula (Ik), characterized in that: The method comprises the following preparation steps: adding N,N'-(propane-1,3-diyl)diacrylamide or N,N'-bis(acryloyl)cystamine and (II) compound, alendronic acid and triethylamine into a flask equipped with a stirring bar, and also adding a mixed solvent of methanol and water into the flask; then reacting in a dark environment at 40-60°C under a nitrogen atmosphere; reacting for 5 to 14 days to produce a highly viscous solution, taking out aliquots for detection at predetermined time intervals to monitor the conversion rate and molar mass, and stopping the reaction by diluting with MeOH once the target molar mass is reached; then acidifying the diluted reaction mixture to an acidic environment with HCl, and then purifying by dialyzing against acidic water, and then freeze-drying the purified product, and collecting the polymer in the form of hydrochloride as a solid after freeze-drying; The structural formula of the compound of formula (II) is as follows: Among them, the range of y / x+y is 0-0.5; L 5 is an optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl or optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted C 3-6 cycloalkenyl, optionally substituted 3 to 8 membered heterocycloalkyl, optionally substituted 3 to 8 membered heterocycloalkenyl, optionally substituted C 6-12 Aryl, optionally substituted 5- to 10-membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkynyl groups are randomly interrupted by one or more heteroatoms; R 3 Yes-OR 11 , -COOR 11 , -SO2OR 11 , (OCH2CH2) m OH, or NR 11 R 12 ; R 11 and R 12 are each independently hydrogen, optionally substituted C 1-12 Alkyl, optionally substituted C 2-12 Alkenyl, optionally substituted C 2-12 Alkynyl, optionally substituted C 3-6 Cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C 6-12 aryl or optionally substituted 5-10 membered heteroaryl, wherein adjacent carbon atoms in the alkyl, alkenyl or alkenyl radical are optionally interrupted by one or more heteroatoms; m is an integer between 1 and 10.

11. A bone-targeted nucleic acid delivery vector, characterized in that: A polymer comprising any one of claims 1 to 9 or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof.

12. A nanocomposite, characterized in that: The invention comprises the polymer or pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof according to any one of claims 1 to 9 and a nucleic acid.

13. The nanocomposite according to claim 12, characterized in that The nucleic acid is selected from at least one of DNA, RNA, plasmid or DNA / RNA hybrid sequence.

14. The nanocomposite according to claim 13, characterized in that The RNA is selected from at least one of agonist RNA, microRNA, short interfering RNA, short hairpin RNA, self-amplifying RNA, interfering RNA and small RNA.

15. The nanocomposite according to claim 13, characterized in that The RNA is a microRNA.

16. The nanocomposite according to any one of claims 12 to 15, characterized in that The weight ratio of the polymer to the nucleic acid is between 5:1 and 100:

1.

17. A nanoparticle, characterized in that: It comprises the polymer according to any one of claims 1 to 9 or a pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph thereof or the nanocomplex according to any one of claims 12 to 16.

18. The nanoparticle according to claim 17, characterized in that The nanoparticles have a hydrodynamic mean diameter D of less than 1000 nanometers. h ; Preferably, the nanoparticles have a hydrodynamic mean diameter D of less than 200 nanometers. h .

19. A pharmaceutical composition, characterized in that Including the polymer or pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph as described in any one of claims 1-9, the polymer prepared by the method for preparing the polymer as described in claim 10, the bone-targeted nucleic acid delivery vector as described in claim 11, the nanocomplex as described in any one of claims 12-16, and the nanoparticle as described in any one of claims 17-18.

20. The pharmaceutical composition according to claim 19, characterized in that Also included are the drug to be delivered and pharmaceutically acceptable excipients.

21. Use of the polymer according to any one of claims 1 to 9 or its pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph, the polymer prepared by the method for preparing a polymer according to claim 10, the bone-targeted nucleic acid delivery vector according to claim 11, the nanocomplex according to any one of claims 12 to 16, the nanoparticle according to any one of claims 17 to 18 in the preparation of drugs for stimulating and enhancing protective immune responses, gene therapy drugs, or drugs for preventing, improving or treating bone-related diseases.

22. Use of the polymer according to any one of claims 1 to 9 or its pharmaceutically acceptable complex, composition, salt, solvate, tautomer or polymorph, the polymer prepared by the method for preparing the polymer according to claim 10, the bone-targeted nucleic acid delivery vector according to claim 11, the nanocomposite according to any one of claims 12 to 16, the nanoparticle according to any one of claims 17 to 18 in the preparation of a drug for stimulating and enhancing a protective immune response, a gene therapy drug, or a drug for preventing, improving or treating a bone-related disease, characterized in that: The bone-related disease is at least one of osteoporosis, osteoarthritis or bone tumor.

Citation Information

Patent Citations

  • Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases

    CN102131509A

  • Preparation method and application of bone targeting gene delivery system

    CN115590973A

  • Bone-targeted nanoparticles for treating osteoporosis

    CN115814107A

  • Preparation method and application of gene delivery system for synergistically treating bone metastatic tumor

    CN117731794A

  • Graft Copolymer Polyelectrolyte Complexes for Drug Delivery

    US20160199502A1